ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

Core Viewpoint - ImmunityBio has received a recommendation from the European Medicines Agency for conditional marketing authorization of ANKTIVA® in combination with BCG for treating BCG-unresponsive non-muscle invasive bladder cancer [1] Company Summary - ImmunityBio is a leading immunotherapy company focused on innovative treatments for cancer [1] Industry Summary - The recommendation from the European Medicines Agency is expected to facilitate early access to new medicines addressing significant unmet medical needs in cancer treatment [1]